多瑞医药 (301075.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−63.6x

Market Cap

CNY 4.30B

MomentumView details →

1D Return

+0.09%

YTD Return

+2.46%

RSI (14)

61.6

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−63.6x

Market Cap

CNY 4.30B

RSI (14)

61.6

MomentumView details →

1D Return

+0.09%

YTD Return

+2.46%

ProfitabilityView details →

Gross Margin

4.94%

Net Margin

−73.30%

EBITDA Margin

−57.52%

ROE (TTM)

−16.29%

ROA (TTM)

−7.57%

Asset Turnover

0.11x

GrowthView details →

Revenue YoY

−35.18%

EPS YoY

−33.14%

FCF YoY

−48.79%

Revenue CAGR 3Y

−27.29%

EPS CAGR 3Y

−63.29%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.24x

Current Ratio

0.73x

Quick Ratio

0.51x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

137.16M

Net Income (TTM)

−100.54M

Op. CF (TTM)

−66.45M

Latest newsMore news →

Duorui Pharmaceutical and its subsidiary Wuhan Jirui Health Industry Investment Co., Ltd. signed agreements to transfer 51% of Quanruinuo and 3.39% of Kairuipu to related party Tibet Jiakang Shidai Technology Development Co., Ltd. for 4.4047 million yuan and 5 million yuan respectively.2d ago

Duorui Pharmaceutical announced the transfer of its 100% equity in subsidiary Hubei Duorui Pharmaceutical to shareholder Tibet Jiakang Times Technology Development for 77.2645 million yuan, constituting a related-party transaction.11d ago

Similar companies

润阳科技300920.SZ 隆华新材301149.SZ 实益达002137.SZ 天振股份301356.SZ 安车检测300572.SZ 开创电气301448.SZ

Latest newsMore news →

Duorui Pharmaceutical and its subsidiary Wuhan Jirui Health Industry Investment Co., Ltd. signed agreements to transfer 51% of Quanruinuo and 3.39% of Kairuipu to related party Tibet Jiakang Shidai Technology Development Co., Ltd. for 4.4047 million yuan and 5 million yuan respectively.2d ago Duorui Pharmaceutical announced the transfer of its 100% equity in subsidiary Hubei Duorui Pharmaceutical to shareholder Tibet Jiakang Times Technology Development for 77.2645 million yuan, constituting a related-party transaction.11d ago Duorui Pharmaceutical announced its first-half 2026 results: net profit attributable to shareholders was 11.5294 million yuan, turning from a loss of 42.5036 million yuan in the same period last year.11d ago